Eli Lilly Gains as Investors Lean Into Obesity Franchise Momentum

Eli Lilly and Company (LLY) is up 3.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to continued confidence in Lilly’s obesity and diabetes franchise rather than a single new filing or earnings release today. This could be because investors are still reacting to several recent positives, including expanded access efforts for weight-loss medicines, encouraging late-stage pipeline updates, and bullish positioning ahead of the next earnings report.

Details:

Lilly recently said its Medicare GLP-1 Bridge program began July 1, 2026, supporting access to Foundayo and Zepbound for eligible patients and reinforcing the company’s push to widen obesity treatment adoption.

The company has continued to publish favorable obesity data, including Phase 3 retatrutide results showing substantial weight loss and added benefits across obesity-related conditions, which strengthened the long-term growth story around its pipeline.

Lilly’s oral obesity drug Foundayo won FDA approval in April 2026, giving the company another major product in a high-demand category beyond injectable treatments.

There does not appear to be a major new SEC filing or company press release today, so part of the gain may reflect momentum buying and upbeat analyst sentiment ahead of second-quarter results.

Sources:

Eli Lilly and Company, AP News, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$LLY Insider Trading Activity

$LLY insiders have traded $LLY stock on the open market 31 times in the past 6 months. Of those trades, 0 have been purchases and 31 have been sales.

Here’s a breakdown of recent trading of $LLY stock by insiders over the last 6 months:

ENDOWMENT INC LILLY has made 0 purchases and 30 sales selling 292,148 shares for an estimated $322,380,730.
ILYA YUFFA (EVP&Pres, LLY USA&Global Capab) sold 2,500 shares for an estimated $2,876,925

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive LLY Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$LLY Hedge Fund Activity

We have seen 1,928 institutional investors add shares of $LLY stock to their portfolio, and 1,746 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

J. STERN & CO. LLP removed 4,042,726 shares (-99.9%) from their portfolio in Q1 2026, for an estimated $3,692,666,355
CAPITAL INTERNATIONAL INVESTORS removed 3,752,688 shares (-38.0%) from their portfolio in Q1 2026, for an estimated $3,427,742,746
CARDANO RISK MANAGEMENT B.V. removed 2,124,209 shares (-89.4%) from their portfolio in Q1 2026, for an estimated $1,940,273,742
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO removed 1,721,029 shares (-13.8%) from their portfolio in Q1 2026, for an estimated $1,572,005,098
FIFTH THIRD BANCORP added 1,497,423 shares (+321.3%) to their portfolio in Q1 2026, for an estimated $1,367,761,142
ASSENAGON ASSET MANAGEMENT S.A. added 1,208,510 shares (+353.7%) to their portfolio in Q1 2026, for an estimated $1,103,865,119
DIAMANT ASSET MANAGEMENT, INC. added 1,069,720 shares (+119923.8%) to their portfolio in Q1 2026, for an estimated $977,092,945

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$LLY Congressional Stock Trading

Members of Congress have traded $LLY stock 10 times in the past 6 months. Of those trades, 5 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $LLY stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 2 purchases worth up to $115,000 on 06/10, 04/14 and 1 sale worth up to $15,000 on 03/13.
REPRESENTATIVE LIZZIE FLETCHER sold up to $15,000 on 04/08.
REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 2 purchases worth up to $30,000 on 04/02 and 0 sales.
REPRESENTATIVE DAVID TAYLOR has traded it 3 times. They made 1 purchase worth up to $15,000 on 02/26 and 2 sales worth up to $30,000 on 02/09, 01/16.
SENATOR ANGUS S. KING JR. sold up to $15,000 on 02/13.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$LLY Analyst Ratings

Wall Street analysts have issued reports on $LLY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 01/20/2026

To track analyst ratings and price targets for $LLY, check out Quiver Quantitative's $LLY forecast page.

$LLY Price Targets

Multiple analysts have issued price targets for $LLY recently. We have seen 13 analysts offer price targets for $LLY in the last 6 months, with a median target of $1285.0.

Here are some recent targets:

Chris Schott from JP Morgan set a target price of $1400.0 on 07/07/2026
Carter Gould from Cantor Fitzgerald set a target price of $1350.0 on 07/06/2026
David Risinger from Leerink Partners set a target price of $1232.0 on 06/25/2026
Akash Tewari from Jefferies set a target price of $1350.0 on 06/09/2026
Jason Gerberry from B of A Securities set a target price of $1251.0 on 05/26/2026
Seamus Fernandez from Guggenheim set a target price of $1183.0 on 05/05/2026
Emily Field from Barclays set a target price of $1400.0 on 05/05/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.